Company Overview

AXIM Biotechnologies, Inc. (OTCQB: AXIM) is a biotechnology and diagnostic research company focused on developing rapid diagnostic testing technologies and proprietary pharmaceutical and nutraceutical products. The company has historically operated in the healthcare and biotechnology sectors, with activities centered on ocular disease diagnostics, immunology-related testing, and cannabinoid-based research initiatives. Public filings and company disclosures indicate that AXIM’s primary strategic focus has shifted over time toward in vitro diagnostic technologies, particularly lateral flow assays and rapid testing platforms.

The company’s principal business activities have included the development of diagnostic products for dry eye disease and inflammatory conditions, as well as intellectual property associated with cannabinoid-based formulations. AXIM has pursued commercialization through research collaborations, licensing arrangements, and subsidiary-led development programs. Historically, the company evolved from a broader cannabinoid therapeutics and nutraceutical strategy into a diagnostics-oriented biotechnology enterprise, reflecting changing market conditions and regulatory considerations in the healthcare and life sciences industries.

Business Operations

AXIM has conducted operations through several business units and subsidiaries focused on diagnostics, biotechnology research, and intellectual property development. The company has referenced activities involving Rapid Test Development, Dry Eye Disease Diagnostics, and cannabinoid-related pharmaceutical research in its public filings. Revenue generation has historically been limited and largely tied to licensing activity, research collaborations, and technology development agreements rather than large-scale commercial product sales. Public disclosures indicate that AXIM has operated primarily as a development-stage biotechnology company, with ongoing efforts to secure regulatory approvals and commercialization pathways.

The company’s operations have included both domestic activities in the United States and research or commercial relationships involving international counterparties. AXIM has controlled or developed proprietary technologies associated with lateral flow immunoassays, ocular diagnostic tools, and cannabinoid delivery systems. Publicly disclosed partnerships and subsidiary activities have included work with diagnostic laboratories, contract manufacturers, and research collaborators. Some historical subsidiaries and affiliated initiatives referenced in filings have undergone strategic restructuring or reduced operational emphasis as the company concentrated resources on diagnostic technologies.

Strategic Position & Investments

AXIM’s strategic direction has centered on expanding its portfolio of rapid diagnostic technologies and strengthening intellectual property assets related to healthcare diagnostics. Company filings and investor materials have emphasized development of point-of-care testing solutions, particularly for inflammatory and ocular conditions. The company has also highlighted efforts to pursue regulatory pathways, patent protection strategies, and commercialization opportunities through licensing and strategic collaborations.

Historically, AXIM invested in cannabinoid-related pharmaceutical research and intellectual property, including oral delivery systems and therapeutic applications. The company has also pursued acquisitions and technology licensing initiatives intended to broaden its diagnostic platform capabilities. Public disclosures have identified emerging interest in rapid testing technologies and decentralized diagnostics as areas of strategic relevance. However, based on available public information, certain commercialization timelines and market adoption expectations remain uncertain, and some development initiatives appear to remain in early or transitional stages. Data inconclusive based on available public sources regarding the long-term commercial scale of several pipeline programs.

Geographic Footprint

AXIM is headquartered in the United States, with operations and corporate activities primarily centered in the U.S. biotechnology and diagnostics market. The company’s public disclosures have referenced research relationships, intellectual property activity, and commercial interactions involving international entities, particularly in Europe and other healthcare research markets. Its operational footprint has historically been modest compared with larger multinational biotechnology companies.

The company’s market presence has primarily focused on North American capital markets and healthcare development initiatives, though certain patent filings, licensing arrangements, and supply-chain relationships have reflected international engagement. AXIM’s influence outside the United States has largely been tied to intellectual property development and collaborative research rather than broad commercial infrastructure or large-scale international distribution operations.

Leadership & Governance

AXIM Biotechnologies has been led by executives with backgrounds in biotechnology development, diagnostics, pharmaceuticals, and public company management. Leadership communications in public filings have emphasized innovation in rapid diagnostics, intellectual property development, and strategic positioning within emerging healthcare technology markets. Governance oversight has been conducted through the company’s board of directors and executive management structure in accordance with public company reporting requirements.

Key executives and leadership figures identified in public disclosures include:

• John W. Huemoeller II – Chief Executive Officer
• Assaf Barnea – Former Chief Executive Officer and Director
• David J. Shapiro – Chief Financial Officer
• George Anastassov, MD, DDS – Former Executive Chairman and strategic advisor associated with cannabinoid and pharmaceutical initiatives

Leadership strategy has generally focused on advancing proprietary diagnostic technologies, pursuing regulatory and commercialization milestones, and leveraging intellectual property assets to support long-term corporate development. Certain executive roles and board positions have changed over time based on company restructuring and strategic realignment activities disclosed in public filings.